Mastelic B Garçon N Del Giudice G Golding H Gruber M Neels P Fritzell B 2013 Vaccination represents one of the greatest public health triumphs; in part due to the effect of adjuvants that have been included in vaccine preparations to boost the immune responses through different mechanisms. Although a variety of novel adjuvants have been under development, only a limited number have been approved by regulatory authorities for human vaccines. This report reflects the conclusions of a group of scientists from academia, regulatory agencies and industry who attended a conference on the current state of the art in the adjuvant field. Held at the U.S. Pharmacopeial Convention (USP) in Rockville, Maryland, USA, from 18 to 19 April 2013 and organized by the International Association for Biologicals (IABS), the conference focused particularly on the future development of effective adjuvants and adjuvanted vaccines and on overcoming major hurdles, such as safety and immunogenicity assessment, as well as regulatory scrutiny. More information on the conference output can be found on the IABS website, http://www.iabs.org/. https://sonar.ch/global/documents/174675 eng info:eu-repo/semantics/altIdentifier/doi/10.1016/j.biologicals.2013.08.006 info:eu-repo/semantics/altIdentifier/pmid/24071553 Biologicals : journal of the International Association of Biological Standardization. - 2013 3-O-desacyl-4′-monophosphoryl lipid A AEs APCs AS Adjuvant BM BNP BVD C-reactive protein CRP DDCs Env FDA Food and Drug Administration GFPDL HA HAI HBV HBsAg HIV-1 Hepatitis B surface antigen Hepatitis B virus ID IFN IM ISCOM LAIV LC LPS Langerhans cells Live Attenuated Influenza Vaccine MIV MM6 MPL MVA Mo MoA Mono Mac 6 NA NHP PBMC PGE2 PLA SC SPADE SPR T follicular helper cells T(FH) TC TIV TLR Vaccine Vaccine safety WHO World Health Organization adjuvant systems adverse events antigen presenting cells bone marrow bovine virus diarrhea dermal dendritic cells envelope glycoprotein genome-fragment phage display libraries hemagglutination-inhibition hemagglutinin human immunodeficiency virus type 1 human primary monocytes immune stimulating complexes induced bovine neonatal pancytopenia interferon intradermal intramuscular lipopolysaccharide mPGES1 microsomal PGE synthase-1 mode of action modified vaccinia ankara monovalent inactivated vaccine nAbs neuraminidase neutralizing antibody non-human primates peripheral blood mononuclear cells poly-lactic prostaglandin E2 rAd5 replication-defective adenovirus 5 spanning-tree progression analysis of density normalized events subcutaneous surface plasmon resonance toll-like receptors transcutaneous trivalent inactivated vaccine Adjuvants, Immunologic Animals Antibody Formation Humans Models, Animal Patient Outcome Assessment Vaccination Vaccines Predictive markers of safety and immunogenicity of adjuvanted vaccines. http://purl.org/coar/resource_type/c_6501